Results 161 to 170 of about 109,968 (264)

Systematic Review of Immunosuppression After Chimeric Antigen Receptor T-Cell Therapy for Posttransplant Lymphoproliferative Disorder. [PDF]

Kidney Int Rep
Synnott D, Bowden A, Sexton DJ.
europepmc   +1 more source

Real time in vivo efficacy monitoring of desialylation and perforation enhanced immunotherapy of cancer

BMEMat, EarlyView.
A multifunctional nanomedicine is designed to engineer NK cells for enhanced cancer immunotherapy through perforation and desialylation, enabling real‐time monitoring of ATP and GrB levels for precise efficacy assessment. Abstract Efficient enhanced NK cell therapy is of critical importance in the immune treatment of cancer.
Yuanjiao Yang, Yuru Wang, Xuemei Li, Chaoyi Yang, Yuhui Yang, Yanyun Fang, Lin Ding, Yunlong Chen, Huangxian Ju   +8 more
wiley   +1 more source

Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma. [PDF]

JCO Clin Cancer Inform
Malek E, Betts B, Herr M, Davila M, Holtan S, Driscoll JJ, Yu H.   +6 more
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Operationalizing Access for Chimeric Antigen Receptor T cell Therapies: A Cross-functional Perspective. [PDF]

Mayo Clin Proc Innov Qual Outcomes
Singh S, Greulich C, Perez A, Terrell K, Walz-Jensen J, Dalzell MD.   +5 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy. [PDF]

Discov Oncol
Pramanik S, Thaker M, Inoue N, Kim PS, Kutzner A, Manavalan A, Pramanik G, Heese K.   +7 more
europepmc   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Patients' and caregivers' perspectives on preparedness for and experience with chimeric antigen receptor T-cell therapy. [PDF]

Oncologist
Barata A, Coffey B, Amonoo HL, Traeger L, Nelson AM, Johnson PC, Dhwale TM, Karpinski K, Jim HSL, El-Jawahri A.   +9 more
europepmc   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source